Duration of anti-HER2 blockage therapy may improve survival in HER2 positive metastatic breast carcinoma patients

Arslan, U.; Turker, I.; Aksoy, S.; Oksuzoglu, B.; Helvaci, K.; Ozdemir, N.; Uyeturk, U.; Sonmez, O.; Budakoglu, B.; Zengin, N.

Duration of anti-HER2 blockage therapy may improve survival in HER2 positive metastatic breast carcinoma patients

Arslan U. Y., Turker I., Aksoy S., Oksuzoglu B., Helvaci K., Ozdemir N. Y., ...More

JOURNAL OF BUON, vol.18, no.3, pp.585-593, 2013 (SCI-Expanded, Scopus)

Publication Type: Article / Article
Volume: 18 Issue: 3
Publication Date: 2013
Journal Name: JOURNAL OF BUON
Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Page Numbers: pp.585-593
Hacettepe University Affiliated: Yes

Abstract

Purpose: The duration of anti-HER2 blockage therapy in metastatic breast cancer patients is still unclear. We aimed to evaluate the effect of the anti-HER2 blockage therapy duration and other factors on survival in HER2 positive metastatic breast carcinoma (MBC) patients.